Tata India Pharma & Healthcare Fund-Direct Plan-Growth
Benchmark: BSE Healthcare TRI · Riskometer: Very High
Tata India Pharma & Healthcare Fund- is a Sectoral/ Thematic mutual fund managed by Tata Asset Management Limited, benchmarked against BSE Healthcare TRI. Riskometer: Very High.
View full analysis on Punji.ai →
LEARN: Growth of ₹100 · NAV · CAGR
CHART
Tata India Pharma & Healthcare Fund- - growth of ₹100
Growth of ₹100 invested on 2021-10-31, not raw NAV - the standard way to compare fund performance regardless of NAV level. Daily resolution for the last 90 days, weekly up to 2 years, monthly beyond that.
NAV History - Last 30 Days(exact daily NAV)
| Date | NAV (₹) | 1D Change |
|---|---|---|
| 2026-10-28 | 37.3629 | +0.4505 (+1.2%) |
| 2026-10-27 | 36.9124 | +0.6762 (+1.9%) |
| 2026-10-26 | 36.2362 | +0.4871 (+1.4%) |
| 2026-10-25 | 35.7491 | +0 (+0%) |
| 2026-10-23 | 35.7491 | -0.3168 (-0.9%) |
| 2026-10-22 | 36.0659 | -0.1044 (-0.3%) |
| 2026-10-21 | 36.1703 | -0.4461 (-1.2%) |
| 2026-10-20 | 36.6164 | +0 (+0%) |
| 2026-10-19 | 36.6164 | -0.3742 (-1%) |
| 2026-10-18 | 36.9906 | +0 (+0%) |
| 2026-10-16 | 36.9906 | +0.0223 (+0.1%) |
| 2026-10-15 | 36.9683 | -0.0684 (-0.2%) |
| 2026-10-14 | 37.0367 | -0.1353 (-0.4%) |
| 2026-10-13 | 37.172 | +0.0538 (+0.1%) |
| 2026-10-12 | 37.1182 | +0.0636 (+0.2%) |
| 2026-10-11 | 37.0546 | +0 (+0%) |
| 2026-10-09 | 37.0546 | +0.127 (+0.3%) |
| 2026-10-08 | 36.9276 | -0.902 (-2.4%) |
| 2026-10-07 | 37.8296 | -0.1617 (-0.4%) |
| 2026-10-06 | 37.9913 | +0.3157 (+0.8%) |
| 2026-10-05 | 37.6756 | -0.3821 (-1%) |
| 2026-10-04 | 38.0577 | +0 (+0%) |
| 2026-10-01 | 38.0577 | -0.2451 (-0.6%) |
| 2026-09-30 | 38.3028 | - |
Punji Fund Health Score - percentile-within-category. See methodology.
CATEGORY COMPARISON
Tata India Pharma & Healthcare Fund- returns
Lumpsum returns: full range of outcomes across every overlapping window in the fund's history for each holding period, not one trailing number.
| Holding period | Min rolling CAGR | Median rolling CAGR | Max rolling CAGR |
|---|---|---|---|
| 1Y | -17.3% | +8.7% | +76.3% |
| 3Y | -3.5% | +21.2% | +30.4% |
Actual point-to-point CAGR for the single best and single worst overlapping window of each holding period in the fund's history - historical fact, not a forecast. Independent of the lumpsum/SIP toggle above - always CAGR-based.
| Holding period | Best window | Worst window | Beat benchmark |
|---|---|---|---|
| 1Y | +76.3% (2020-03-23 → 2021-03-23) | -17.3% (2016-09-08 → 2017-09-08) | 12.3% |
| 3Y | +30.4% (2018-06-05 → 2021-06-04) | -3.5% (2016-01-29 → 2019-01-28) | 13.11% |
Tata India Pharma & Healthcare Fund- category rank vs peers
| Metric | Value | Rank | Category median |
|---|---|---|---|
| 3Y Rolling CAGR | 21.2% | #20 of 102 | 17.4% |
| 3Y Sharpe Ratio | 0.62 | #16 of 108 | 0.23 |
| 3Y Alpha | -2.6% | #95 of 107 | 1.2% |
| 3Y Std Deviation | 14.3% | #36 of 108 (lower is better) | 15.2% |
| Total Expense Ratio | 1.00% | #27 of 174 (lower is better) | 1.20% |
| AUM | ₹1,431 Cr | #77 of 174 | ₹1,271 Cr |
| 3Y Max Drawdown | 16.81% | #25 of 108 (lower is better) | 20.66% |
Tata India Pharma & Healthcare Fund- risk metrics
0.6177
0.9093
-2.6362
0.9038
14.2522
-16.8059
88.5809
90.8866
4.3849
0.9439
3-year window vs. BSE Healthcare TRI.
Tata India Pharma & Healthcare Fund- holdings
Portfolio as of 2026-09-30
Hold multiple funds? See our Portfolio Overlap Tool to see if they actually hold different stocks.
CHART
Top sector holdings
Share of portfolio (% to NAV) in each of the top sectors.
TOP HOLDINGS
Funds similar to Tata India Pharma & Healthcare Fund-
Top funds in the same category, ranked by performance - not holdings overlap. Pick up to 2 to compare alongside this fund:
Tata India Pharma & Healthcare Fund- Punji analytics
ADVANCED RISK-ADJUSTED METRICS
3-year window vs. BSE Healthcare TRI. Not commonly published by other Indian fund platforms.
CHART
Asset Allocation
As of Sep-2026
CHART
Market Cap Split
As of Sep-2026
Portfolio analytics as of Sep-2026.
Frequently asked questions
How often has Tata India Pharma & Healthcare Fund- beaten its benchmark over 3-year periods?
Tata India Pharma & Healthcare Fund- beat its benchmark, BSE Healthcare TRI, in 13.11% of all overlapping 3-year rolling windows in its history. This is different from simply having a positive return - it measures how often the fund's own 3-year CAGR exceeded the benchmark's 3-year CAGR over the exact same dates, which is a more direct read on the manager's stock selection than a single trailing alpha figure computed over one window.
What is Tata India Pharma & Healthcare Fund-'s 3-year rolling return, and how does it rank?
Tata India Pharma & Healthcare Fund-'s 3-year rolling CAGR (median across all rolling 3-year windows in the data) is 21.2%. That places it in the 81st percentile within its category, Sectoral/ Thematic - meaning it has outperformed roughly 81% of peers in the same category over this window. The category median for this metric is 17.4%, so comparing Tata India Pharma & Healthcare Fund-'s figure against that median shows how much it has beaten (or trailed) a typical fund in this category. Rolling returns average performance across many overlapping windows rather than a single start/end date, which makes them a steadier read on consistency than a simple point-to-point return.
How risky is Tata India Pharma & Healthcare Fund-?
Tata India Pharma & Healthcare Fund- carries a "Very High" risk rating on SEBI's mandated riskometer scale, the same standardized classification every Indian mutual fund must disclose. This rating reflects the fund's underlying portfolio composition and historical volatility, and is set independently of any single AMC's own marketing - it's meant to give investors a comparable, at-a-glance sense of how much the fund's value can swing before deciding whether it matches their own risk appetite and investment horizon. A higher-risk rating isn't inherently bad; it typically correlates with higher long-term return potential, but also with larger short-term drawdowns, so it should be read alongside the fund's category and your own time horizon rather than in isolation.
What is Tata India Pharma & Healthcare Fund-'s expense ratio?
Tata India Pharma & Healthcare Fund-'s direct-plan expense ratio is 1% per year - the annual fee the AMC deducts from the fund's assets to cover management and operating costs, already reflected in the NAV you see (it isn't billed separately). Direct plans skip the distributor commission built into Regular plans, which is why a direct-plan expense ratio is almost always lower than the same scheme's Regular-plan version. Over long holding periods, even a difference of a few basis points compounds into a meaningfully different final corpus, which is why expense ratio is one of the few fund attributes an investor can compare with total certainty before investing, unlike future returns.
How does Tata India Pharma & Healthcare Fund-'s expense ratio compare to its category?
Tata India Pharma & Healthcare Fund-'s expense ratio of 1.00% ranks #27 of 174 funds in the Sectoral/ Thematic category (lower is better) - the category median is 1.20%. Expense ratio is deducted from the fund's assets every year regardless of performance, so a lower ratio is a real, certain cost advantage rather than a projection, unlike future returns.
How big is Tata India Pharma & Healthcare Fund-, and how does that compare to its category?
Tata India Pharma & Healthcare Fund- manages ₹1,431 Cr in assets, ranking #77 of 174 funds by size in the Sectoral/ Thematic category - the category median is ₹1,271 Cr. A larger fund generally means deeper liquidity and lower per-unit fixed costs for the AMC to spread across investors, but in categories with a smaller investable universe (like small or mid cap), a very large fund can also face more difficulty entering and exiting positions without moving the price.
What's the worst drawdown Tata India Pharma & Healthcare Fund- has experienced, and how does that compare to its category?
Tata India Pharma & Healthcare Fund-'s worst peak-to-trough decline over the last 3 years was 16.81%, ranking #25 of 108 funds in the Sectoral/ Thematic category (lower is better) - the category median is 20.66%. Max drawdown measures the deepest loss an investor holding through the worst stretch would have seen, before any recovery - a smaller number means a gentler ride, though it says nothing about how long the fund took to recover.
How has Tata India Pharma & Healthcare Fund- performed against its benchmark, BSE Healthcare TRI?
Over a 3-year window, Tata India Pharma & Healthcare Fund- has underperformed its benchmark, BSE Healthcare TRI, by 2.6% (alpha). Alpha measures the fund's return in excess of what its benchmark alone would have delivered, after adjusting for the risk taken (beta of 0.90 here) - a positive alpha means the fund manager's stock selection and allocation calls added real value beyond simply tracking the market, while a negative alpha means the fund would have been better replicated by a low-cost index fund tracking the same benchmark. This is a trailing, historical figure and isn't a guarantee of future outperformance.
What's the best and worst 3-year holding period for Tata India Pharma & Healthcare Fund- historically?
Looking at every overlapping 3-year window in Tata India Pharma & Healthcare Fund-'s history, the best-performing window ran from 2018-06-05 to 2021-06-04, delivering a 30.4% CAGR. The worst-performing window ran from 2016-01-29 to 2019-01-28, delivering a -3.5% CAGR. This is a historical record of actual past outcomes, not a prediction - it shows the real range of results an investor holding for exactly 3 years could have seen depending on entry timing, which is why rolling returns (median across all windows, shown above) are a more representative single number than either extreme.
How concentrated are Tata India Pharma & Healthcare Fund-'s top holdings?
Tata India Pharma & Healthcare Fund-'s single largest disclosed holding, SUN PHARMACEUTICAL INDUSTRIES LTD, accounts for 7.99% of NAV. Its top 5 holdings together make up 30.2% of the portfolio, and its top 10 disclosed holdings make up 50.5% - as of 2026-09-30. A higher concentration in the top few names means the fund's returns lean more heavily on those specific bets paying off, while a flatter spread means no single holding drives outcomes as much either way.
Who manages Tata India Pharma & Healthcare Fund-, and what category does it belong to?
Tata India Pharma & Healthcare Fund- is managed by Tata Asset Management Limited and is classified under the Sectoral/ Thematic category, the SEBI-defined scheme categorization that groups funds by their investment mandate (market-cap focus, sector, or asset mix) so investors can compare like-for-like funds rather than across unrelated strategies. The AMC (asset management company) is the regulated entity legally responsible for the fund's operations, portfolio decisions, and disclosures, though day-to-day investment calls are made by a designated fund manager within the mandate set by the scheme's category and stated objective.
Data as of 2026-10-29. Source: AMFI disclosures via Punji. Not investment advice.